Prescribing pattern and cost analysis of antihypertensives in India

Vummareddy, Hemalatha; Mudhaliar, Mohanraj Rathinavelu; Ishrar, Shaik Mohammad Ghouse; Sandyapakula, Balaiah; Vobbineni, Lokesh; Thomas, Bijoy

doi:10.4103/2348-3334.201995

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to (Mudhaliar et al, 2017) the cost of anti hypertensive medication (average per patient) is Rs 3823.58 /-per year indicating Rs 1911.79 /-which is nearly similar to our study as it marginal higher than the cost of our study observations. According to (Rachana et al, 2014) cost of anti hypertensive medication of monotherapy is Rs 2362.69 + 1521.67, polytherapy is Rs 2525.72 + 853.33, ixed dose combination is Rs 2576.48 + 1399.47 per year.…”

Section: Cost Analysissupporting

confidence: 87%

Current prescription status of anti hypertensives in cardiology

Ali

Singh

Shrivastava

et al. 2020

ijrps

View full text Add to dashboard Cite

The main of our study is to determine the prescription pattern and perform cost analysis of the patients who were visiting the cardiology department of the hospital. Anti hypertensive drugs has vast classification and most of the studies suggest that cardiovascular events are one among the most leading contributor to global patients in regards to mortality and morbidity. Cardiovascular events are also considered as silent killer because its symptoms are unpredictable. should be prescribed properly. So we have undergone a prospective observational study which shows mean age of 60.13 + 9.22. We found that there is much difference in gender for exposure of cardiovascular events. We observed dual therapy was effective in management for . We found total average of direct medical cost was Rs.5641.12 and indirect medical cost was Rs.677.27. The patients prescription was and documented to know the level of and compliance with guidelines. The economic burden experienced by the patients were to know the rational use of drugs and to lay a way for further research related to economics.

show abstract

Section: Cost Analysissupporting

confidence: 87%

Current prescription status of anti hypertensives in cardiology

Ali

Singh

Shrivastava

et al. 2020

ijrps

View full text Add to dashboard Cite

show abstract

Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells

Vaibavi

Sivasubramaniapandian

Vaippully

et al. 2021

Cell Biochem Biophys

View full text Add to dashboard Cite

Asian management of hypertension: Current status, home blood pressure, and specific concerns in India

Sogunuru

Mishra

2020

J of Clinical Hypertension

View full text Add to dashboard Cite

Systemic hypertension and its related complications are the important contributing factors for major adverse cardiovascular events all over the world. Evidence from Asia and even from India reveals that both its incidence and prevalence are increasing even in young population both in urban and rural areas. The HOPE (Hypertension Cardiovascular Outcome Prevention and Evidence) Asia network data clearly say that

show abstract

Prescribing pattern and cost analysis of antihypertensives in India

Cited by 3 publications

References 0 publications

Current prescription status of anti hypertensives in cardiology

Current prescription status of anti hypertensives in cardiology

Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells

Asian management of hypertension: Current status, home blood pressure, and specific concerns in India

Contact Info

Product

Resources

About